bioRxivMicrobiology
Membrane Nanoparticles Derived from ACE2-rich Cells Block SARS-CoV-2 Infection
C. Wang, S. Wang, Y. Chen, J. Zhao, S. Han, G. Zhao, J. Kang, Y. Liu, L. Wang, X. Wang, Y. Xu, S. Wang, Y. Huang, J. Wang, J. Zhao
Abstract
The ongoing COVID-19 epidemic worldwide necessitates the development of novel effective agents against SARS-CoV-2. ACE2 is the main receptor of SARS-CoV-2 S1 protein and mediates viral entry into host cells. Herein, the membrane nanoparticles prepared from ACE2-rich cells are discovered with potent capacity to block SARS-CoV-2 infection. The membrane of human embryonic kidney-239T cell highly expressing ACE2 is screened to prepare nanoparticles. The nanomaterial termed HEK-293T-hACE2 NPs contains 265.1 ng mg-1 of ACE2 on the surface and acts as a bait to trap SARS-CoV-2 S1 in a dose-dependent manner, resulting in reduced recruitment of the viral ligand to host cells. Interestingly, SARS-CoV-2 S1 can translocate to the cytoplasm and affect the cell metabolism, which is also inhibited by HEK-293T-hACE2 NPs. Further studies reveal that HEK-293T-hACE2 NPs can efficiently suppress SARS-CoV-2 S pseudovirions entry into human proximal tubular cells and block viral infection with a low half maximal inhibitory concentration. Additionally, this biocompatible membrane nanomaterial is sufficient to block the adherence of SARS-CoV-2 D614G-S1 mutant to sensitive cells. Our study demonstrates a easy-to-acheive memrbane nano-antagonist for curbing SARS-CoV-2, which enriches the existing antiviral arsenal and provides new possibilities to treat COVID-19. O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=182 SRC="FIGDIR/small/247338v1_ufig1.gif" ALT="Figure 1"> View larger version (81K): org.highwire.dtl.DTLVardef@4086baorg.highwire.dtl.DTLVardef@4d239eorg.highwire.dtl.DTLVardef@5d8b76org.highwire.dtl.DTLVardef@16f2581_HPS_FORMAT_FIGEXP M_FIG Graphical Table of Contents C_FIG
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Nanotraps for the containment and clearance of SARS-CoV-2
M. Chen, J. Rosenberg, … J. Huang·bioRxiv·Feb 1, 2021
- hACE2 peptide mimics block SARS-CoV-2 Pulmonary Cells Infection
P. Karoyan, V. Vieillard, … O. Lequin·bioRxiv·Aug 24, 2020
- ACE2-Coated Virus-Like Particles Effectively Block SARS-CoV-2 Infection
C. Bayraktar, A. Kayabolen, … T. Bagci-Onder·bioRxiv·Sep 19, 2023
- Circulating ACE2-expressing Exosomes Block SARS-CoV-2 Virus Infection as an Innate Antiviral Mechanism
L. El-Shennawy, A. D. Hoffmann, … H. Liu·bioRxiv·Dec 3, 2020
- High Affinity Nanobodies Block SARS-CoV-2 Spike Receptor Binding Domain Interaction with Human Angiotensin Converting Enzyme
T. J. Esparza, N. P. Martin, … D. L. Brody·bioRxiv·Jul 24, 2020
- Novel ACE2 nanoparticles universally block SARS-CoV-2 variants in the human respiratory tract
C. Sauvanet, M. Lemos, … D. Hanein·bioRxiv·May 5, 2022